Elutia to Present at the 16th Annual LD Micro Invitational on May 18th

(Neutral)

Rhea-AI Summary

Elutia (Nasdaq: ELUT) announced that CEO Dr. Randy Mills and CFO Matt Ferguson will present at the 16th Annual LD Micro Invitational on May 18, 2026, at the Luxe Sunset Boulevard Hotel in Los Angeles.

Management will discuss Elutia’s drug-eluting biomatrix technology for implant-based breast reconstruction and its role in addressing post-surgical infection, a leading cause of complications and revision surgeries. The presentation begins at 11:30 a.m. Pacific Time and will be available via live webcast. Elutia will also host one-on-one investor meetings on May 18, 2026.

News Market Reaction – ELUT

-0.96%

-0.96% Session close to close

In the May 15 session, ELUT declined 0.96%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement underscores Elutia’s continued effort to showcase its drug-eluting biomatrix platf...

Analysis

This announcement underscores Elutia’s continued effort to showcase its drug-eluting biomatrix platform and focus on post-surgical infection in implant-based breast reconstruction. The company has recently emphasized strategic reshaping and regulatory progress on NXT-41, alongside regaining full Nasdaq compliance on March 4, 2026. Investors may watch how management frames its focused Women’s Health opportunity, updates on regulatory timelines, and any commentary that builds on prior earnings and 10-K disclosures about its streamlined business model.

Key Figures

Conference date: May 18, 2026 Conference edition: 16th Presentation time: 11:30 am Pacific Time

3 metrics

Conference date May 18, 2026 Date of LD Micro Invitational presentation

Conference edition 16th 16th Annual LD Micro Invitational

Presentation time 11:30 am Pacific Time Scheduled start time on May 18, 2026

Historical Context

5 past events · Latest: Apr 30 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 30	Earnings call date	Neutral	-1.0%	Scheduled Q1 2026 results release and conference call announcement.
Mar 17	Investor conference	Positive	+1.9%	Sidoti small-cap conference presentation on biomatrix technology and infections.
Mar 13	Inducement awards	Negative	-6.1%	Grant of 460,000 stock options under 2026 Inducement Award Plan.
Mar 11	Earnings & pipeline	Positive	+5.5%	Q4/FY 2025 results and initiation of NXT-41 regulatory process.
Mar 04	Nasdaq compliance	Positive	-2.5%	Regained compliance with Nasdaq minimum bid and market value rules.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often saw aligned reactions, with positive strategic or earnings updates drawing gains, while compliance and inducement items saw mixed or negative moves.

Recent Company History

Over the past few months, Elutia has focused on strategic repositioning and capital structure cleanup. In March 2026, it reported Q4 and full-year 2025 results with improved losses and regulatory progress on NXT-41, which coincided with a 5.5% gain. The company also regained full Nasdaq compliance on March 4, 2026, though shares fell 2.46%. Routine equity and inducement awards on March 13, 2026 preceded a 6.09% decline. A March investor conference appearance saw a modest 1.87% rise, framing today’s LD Micro presentation as a continuation of its investor outreach.

Key Terms

drug-eluting biomatrix, implant-based breast reconstruction, mastectomy

3 terms

drug-eluting biomatrix medical

"a pioneer in drug-eluting biomatrix technologies, today announced that"

A drug-eluting biomatrix is a medical implant or coating made of biocompatible material that slowly releases a drug at a controlled rate where it is placed in the body, like a sponge that steadily releases medicine into surrounding tissue. For investors, it matters because such technology can improve treatment effectiveness, reduce side effects and repeat procedures, and therefore influence product value, regulatory risk and long-term revenue potential for medical-device and pharmaceutical companies.

implant-based breast reconstruction medical

"address post-surgical infection in implant-based breast reconstruction following mastectomy"

A surgical approach that rebuilds a breast using a manufactured implant—usually saline or silicone—placed under the chest muscle or skin after breast tissue is removed or damaged. For investors, it signals demand for specific medical devices, surgical consumables and related services, and brings exposure to product safety rules, reimbursement policies and litigation risk; think of it like replacing a removed car part with an aftermarket component.

mastectomy medical

"implant-based breast reconstruction following mastectomy—one of the most significant challenges"

Mastectomy is a surgical procedure that removes all or part of breast tissue, usually to treat or prevent breast cancer. Investors follow mastectomy trends because changes in how often or which type of mastectomy is performed can affect demand for related drugs, medical devices, reconstructive services and insurance payouts—think of it like a market signal that shifts which products and services hospitals and patients will need.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/14/2026 - 04:01 PM

GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present and host one-on-one meetings with investors at the 16^th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California on May 18, 2026.

During the presentation, management will discuss how Elutia is working to address post-surgical infection in implant-based breast reconstruction following mastectomy—one of the most significant challenges facing patients and surgeons—through its drug-eluting biomatrix technology designed to support safer, more reliable reconstructive outcomes.

The Company will highlight its focus on improving outcomes in implant-based breast reconstruction, where infection remains a leading cause of complications and revision surgeries for patients undergoing reconstruction after breast cancer treatment.

The presentation will begin at 11:30 am Pacific Time on May 18, 2026, and can be accessed live here: WEBCAST LINK. Elutia will also host one-on-one meetings with investors on May 18, 2026. To register for the presentation or schedule a one-on-one meeting, visit LD Micro.

About LD Micro
LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Through its dynamic, investor-driven conferences and curated company exposure, LD has served as an invaluable asset to all those interested in discovering the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.

About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:
Elutia Investor Relations
ir@elutia.com

FAQ

When will Elutia (Nasdaq: ELUT) present at the 16th Annual LD Micro Invitational 2026?

Elutia will present on May 18, 2026, at 11:30 a.m. Pacific Time. According to Elutia, the event takes place at the Luxe Sunset Boulevard Hotel in Los Angeles and includes both a formal presentation and one-on-one investor meetings that same day.

What topic will Elutia (ELUT) management cover at the LD Micro Invitational presentation?

Elutia’s management will discuss its drug-eluting biomatrix technology for implant-based breast reconstruction. According to Elutia, the presentation focuses on addressing post-surgical infection after mastectomy and supporting safer, more reliable reconstructive outcomes for breast cancer patients undergoing implant-based reconstruction.

How can investors access Elutia’s May 18, 2026 LD Micro Invitational webcast?

Investors can access Elutia’s presentation via a live webcast link provided for the May 18, 2026 session. According to Elutia, the webcast begins at 11:30 a.m. Pacific Time and offers real-time access to management’s discussion of its breast reconstruction technology.

Will Elutia (ELUT) hold one-on-one investor meetings at the 2026 LD Micro Invitational?

Yes, Elutia will host one-on-one investor meetings on May 18, 2026. According to Elutia, interested investors can register for the presentation or schedule individual meetings through LD Micro, creating direct opportunities to engage with company leadership about its biomatrix technology.

What medical need is Elutia addressing in its LD Micro Invitational 2026 presentation?

Elutia is addressing post-surgical infection in implant-based breast reconstruction after mastectomy. According to Elutia, infection remains a leading cause of complications and revision surgeries, and its drug-eluting biomatrix technology is designed to support safer, more reliable reconstructive outcomes for these patients.